![Alliance News](https://static.lse.co.uk/images/news-logos/alliance-news-logo.png)
TRADING UPDATES: Powerhouse resolves claim; PCI-PAL wins court case
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read moreMon, 11th Oct 2021 15:00
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more(Alliance News) - Polarean Imaging PLC on Tuesday said that it intends to raise a minimum of USD10 million via a placing to institutional and other investors, and a direct subscription with the company.
Read more(Alliance News) - Stock prices in London were up at midday on Friday, hitting a record high once again as investors reacted positively to a dovish Bank of England interest rates hold.
Read more(Sharecast News) - Advanced MRI technology specialist Polarean Imaging shares were surging on Friday, after receiving its second de novo order for a new Xenon MRI System from the University of Alabama at Birmingham (UAB) Hospital.
Read more(Alliance News) - Polarean Imaging PLC on Friday said it has received its second de novo order for a new Xenon MRI system from the University of Alabama at Birmingham Hospital in the US.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.
Read morePolarean Imaging PLC - London-based medical imaging technology developer - Receives an order for a new polariser to replace the research polariser at Cincinnati Children's Hospital Medical Center. "Cincinnati Children's previously purchased the first clinical polariser and continues to demonstrate a commitment to the future of Xenon MRI for challenging lung diseases. Cincinnati Children's performs hospital clinical imaging on both children and adults (from their neighbouring partner institution, UC Medical Centre)," Polarean says.
Read more(Sharecast News) - Polarean Imaging announced a new polariser order to replace the research polariser at Cincinnati Children's Hospital Medical Center on Friday.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - Polarean Imaging PLC shares dropped on Thursday, after the company said it would need to find an additional USD10 million to finance its medium-term ambitions.
Read morePolarean Imaging PLC - London-based developer of medical imaging devices providing magnetic resonance imaging of the lungs - Strategic partner NUKEM Isotopes GmbH buys 9.5 million Polarean shares from Amati Global Investors Ltd, raising its stake to 10.5% from 6.1%. Alzenau, Germany-based NUKEM is a trading company in stable isotopes and noble gases. Amati retains a 4.6% stake in Polarean, down from its last reported level of 9.8%. The shares purchased by NUKEM are worth GBP725,800 at Polarean's current market price.
Read more(Sharecast News) - Lung-focussed MRI technology developer Polarean Imaging said in an update on Thursday that it has received its first de novo order for a new Xenoview polariser.
Read morePolarean Imaging PLC - London-based medical imaging technology developer - Receives its first de novo order for a new Xenoview polariser from an unnamed "top-tier" academic medical centre located in the northeast of the US. Polarean says it continues to have positive meetings and is in active negotiations with additional academic medical centres. Xenoview is a hyperpolarised contrast agent for use with magnetic imaging for the evaluation of lung ventilation in adults and paediatric patients aged 12 years and older. It was approved for use in the US last year.
Read more(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.
Read more(Sharecast News) - Advanced MRI technology specialist Polarean Imaging announced a strategic partnership with a clinical imaging intelligence company VIDA Diagnostics on Friday.
Read more